Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome

Inclusion Criteria: * Age ≥ 18 to ≤ 74 years. * Able and willing to voluntarily complete the informed consent process. * Available for, and agree to, all study procedures, including fixed diet, feces, urine, and blood * collection, follow-up visits, and compliance with all study procedures. * History of gastric bypass surgery (at least 12 months prior to Day 1) or short-bowel * syndrome. * If taking probiotic supplements (enriched foods excluded), has been on a stable, well tolerated dose for at least 2 weeks prior to Day 1. * Women of childbearing potential must have a negative pregnancy test (human chorionic * gonadotropin) at screening and at baseline prior to the start of IMP. * Screening laboratory evaluations (e.g., chemistry panel, complete blood count with * differential, prothrombin time, urinalysis) and electrocardiogram (ECG) must be within * normal limits or judged not to be clinically significant by the investigator. Subjects with * known diabetes should be well controlled and have an A1c of ≤ 8% within 3 months prior to Day 1. * Agree to abstain from tobacco/nicotine use for the duration of the inpatient stay. * Subjects who are HIV positive, on therapy with normal CD4 counts and undetectable viral loads, can be included. Exclusion Criteria: * Acute or chronic medical (including COVID-19 infection), surgical, psychiatric, or social condition or laboratory abnormality (except those that can be explained by malabsorption) that may increase subject risk associat…